Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04208347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2024 to Dec 2026 Completion date: Aug 2025 to Dec 2027v6 Show 1 more changeShow less
    • Completion date: Aug 2025 to Dec 2027
  2. Primary completion date: Aug 2023 to Dec 2024 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 23 of 23 sitesv5 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 23 of 23 sites
  3. Enrollment target: 258 to 580 Primary completion date: Jul 2021 to Aug 2023 · Primary endpoints: 1 to 2 · Completion date: Oct 2022 to Aug 2025 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Jul 2021 to Aug 2023
    • Primary endpoints: 1 to 2
    • Completion date: Oct 2022 to Aug 2025
    • Secondary endpoints: 7 to 6

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 1 to 23v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2019 to Dec 18, 2019v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2019 to Dec 18, 2019
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ruijin Hospital
370 trials monitored
See 13 trials at risk
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Trial Details
NCT Number NCT04208347
Lead Sponsor Ruijin Hospital
Conditions Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment 580 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov